Irreversible blindness in juvenile systemic lupus erythematosus. 2011

R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
Pediatric Rheumatology Unit, Children's Hospital, Hospital das Clínicas da Faculdade de Medicina da Universidade São Paulo, São Paulo, Brazil.

Blindness caused by severe vasculitis or uveitis is rare in juvenile systemic lupus erythematosus (JSLE) patients. In a 27-year period, 5367 patients were followed at our Paediatric Rheumatology Division and 263 (4.9%) patients had JSLE (American College of Rheumatology criteria). Of note, two (0.8%) of them had irreversible blindness. One of them presented with cutaneous vasculitis and malar rash, associated with pain and redness in both eyes, impairment of visual acuity due to iridocyclitis and severe retinal vasculitis with haemorrhage. Another patient had peripheral polyneuropathy of the four limbs and received immunosuppressive drugs. Three weeks later, she developed diffuse herpes zoster associated with acute blindness due to bilateral retinal necrotizing vasculitis compatible with varicella zoster virus ocular infection. Despite prompt treatment, both patients suffered rapid irreversible blindness. In conclusion, irreversible blindness due to retinal vasculitis and/or uveitis is a rare and severe lupus manifestation, particularly associated with disease activity and viral infection.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D001766 Blindness The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE. Amaurosis,Bilateral Blindness,Blindness, Bilateral,Blindness, Legal,Blindness, Monocular,Blindness, Unilateral,Sudden Visual Loss,Unilateral Blindness,Blindness, Acquired,Blindness, Complete,Blindness, Hysterical,Blindness, Transient,Acquired Blindness,Amauroses,Bilateral Blindnesses,Complete Blindness,Hysterical Blindness,Legal Blindness,Monocular Blindness,Sudden Visual Losses,Transient Blindness,Visual Loss, Sudden
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D014657 Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body. Angiitis,Angiitides,Vasculitides
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
October 1993, British journal of rheumatology,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
January 1989, La Revue de medecine interne,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
March 2017, Lupus,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
January 2012, Acta reumatologica portuguesa,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
September 1997, Arquivos de neuro-psiquiatria,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
November 2014, Indian pediatrics,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
September 2005, Current opinion in rheumatology,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
January 2009, Arthritis and rheumatism,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
January 2007, Lupus,
R T Almeida, and N E Aikawa, and A M E Sallum, and A A Jesus, and L C F Sa, and C A Silva
January 2015, Autoimmunity,
Copied contents to your clipboard!